Satellite Symposium

These symposia programs are not part of the ACEP25 educational program as planned by ACEP’s Educational Meetings Subcommittee.

Seating is first-come, first-served and a meal will be provided.

Let’s discuss RENOVATE: Remodeling your management of respiratory failure

  • Grantor: Fisher & Paykel Healthcare
  • When: Monday, September 8 | 6:30 am – 7:30 am
  • Location: Hyatt Regency Salt Lake City, Level 2, Salt Lake B

This Satellite Symposium will introduce and examine the RENOVATE Randomized Clinical Trial (Maia et al. High-Flow Nasal Oxygen vs Noninvasive Ventilation in Patients with Acute Respiratory Failure: The RENOVATE Randomized Clinical Trial. JAMA 2024), then describe the relevance, importance and application [of the trial findings] in US Emergency Departments.

As event Chair, Dr. James Neuenschwander will open the Symposium, then state the trial question and relevance for the US [is high-flow nasal oxygen noninferior to noninvasive ventilation in patients with ARF, introduce the keynote speaker, then the speakers describing the relevance, importance and application of the trial findings.

Symposium Objectives:

  1. Introduce and examine the RENOVATE Randomized Clinical Trial
  2. Examine the relevance of the trial findings in US Emergency Departments
  3. Identify the application opportunities for the trial findings in US Emergency Departments

FACULTY

Chair:
Dr. James Neuenschwander
Emergency Physician, Doctors Hospital, Columbus, OH
Adjunct Associate Professor, The Ohio State Medical Center

Keynote Speaker:
Dr. Israel Maia
Professor at Federal University of Santa Catarina, Brazil
Principal Investigator for The RENOVATE Randomized Clinical Trial

Speaker:
Dr. Deborah Diercks
Professor and Chair of Emergency Medicine
UT Southwestern Medical Center, Dallas, TX

Speaker:
Dr. Emily Gundert
Associate Professor Emergency Medicine
UT Southwestern Medical Center, Dallas, TX

Severe Abdominal Pain: Could it be a Hepatic Porphyria Attack? What the ER physician needs to know

  • Supported through an educational grant from: RECORDATI RARE DISEASES
  • When: Monday, September 8 | 6:30 am – 7:30 am
  • Location: Hyatt Regency Salt Lake City, Level 2, Salt Lake A

The acute or inducible hepatic porphyrias comprise four inherited disorders of heme biosynthesis: acute intermittent porphyria (AIP), ALAD porphyria (ADP), hereditary coproporphyria (HCP), and variegate porphyria (VP). Often remaining asymptomatic for most of the lifespan of individuals who inherit specificenzyme deficiencies, hepatic porphyrias may cause life-threatening attacks of neurovisceral symptoms. Failure to consider the diagnosis frequently delays effective treatment, and inappropriate diagnostic tests and/or mistaken interpretation of results may lead to misdiagnosis and inappropriate treatment.

The diagnosis of one of these acute porphyric syndromes should be considered in many patients with otherwise unexplained intense abdominal pain, severe constipation, systemic arterial hypertension, or other characteristic symptoms that can be seen in the emergency room setting. Intensely painful attacks can be life-threatening if incorrectly diagnosed, representing a significant healthcare provider knowledge and practice gap. Intravenous hemin therapy is the treatment of choice for all but mild attacks of the acute porphyrias and should be started as soon as possible. To close these practice gaps, our AHP expert will discuss treatment strategies and provide recommendations using real patient cases seen in the ER setting.

Symposium Objectives:

  1. Discuss the clinical manifestations of AHP to prompt an earlier diagnosis
  2. Recognize signs and symptoms of AHP in the ER setting: neurovisceral and other acute symptoms
  3. Using sample patient cases, employ strategies to manage attacks in the ER setting

FACULTY

Akshata Moghe, MD, PhD
Assistant Professor, Department of Internal Medicine
Division of Gastroenterology, Hepatology, and Nutrition
University of Texas Health Science Center
Houston, TX

This is a CME presentation.

EXCEL Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

EXCEL Continuing Education designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Amyloid-Targeting Therapies for Alzheimer’s Disease: A Perspective for Emergency Physicians

  • Grantor: Eli Lilly and Company
  • When: Tuesday, September 9 | 6:30 am – 7:30 am
  • Location: Hyatt Regency Salt Lake City, Level 2, Salt Lake A

The symposium seeks to introduce emergency physicians and other emergency healthcare professionals to novel amyloid-targeting therapies for treatment of early symptomatic Alzheimer’s disease. Use of these novel medications requires treatment monitoring, with specific emphasis on clinical and radiographic (via MRI) surveillance for Amyloid-Related Imaging Abnormalities (ARIA) and Infusion-Related Reactions (IRR). These requirements rely on a multidisciplinary approach involving memory care specialists, radiologists, primary care, and emergency care providers. Emergency care providers and staff play a crucial role in evaluation and management of symptomatic cases of both ARIA and IRR. The symposium will provide an overview of the novel amyloid-targeting agents, their intended indication for treatment of early symptomatic Alzheimer’s disease, the multidisciplinary approach to treatment monitoring, the identification of ARIA and IRR, as well as practical guidance for management in emergency care settings. This is a non-CME program.

Symposium Objectives:

  1. Introduce emergency physicians to amyloid-targeting therapies for the treatment of Alzheimer’s disease
  2. Review the multidisciplinary approach to treatment initiation and monitoring for patients
    on amyloid-targeting therapies, including multi-directional communication between
    team members
  3. Discuss amyloid-related imaging abnormalities (ARIA) and infusion-related reactions (IRR) associated with amyloid-targeting therapies, including symptomatic presentations in emergency care settings

FACULTY

Dani Cabral, MD

[ Feedback → ]